-
s CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis
- Source: Current Pharmaceutical Design, Volume 29, Issue 39, Nov 2023, p. 3166 - 3169
-
- 01 Nov 2023
Preview this article:
CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis, Page 1 of 1
< Previous page Next page > /docserver/preview/fulltext/cpd/29/39/s7-1.gif
There is no abstract available.
© Bentham Science Publishers